SCHEMBL16748017

SCHEMBL16748017

Cc1cc(Cl)nc(Nc2ccccc2N)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.63
MEN1 O00255 5/20 0.63
GAA P10253 8/20 0.47
MAPT P10636 7/20 0.47
TDP1 Q9NUW8 2/20 0.47
MAPK10 P53779 1/20 0.46
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
STAT1 P42224 1/20 0.42
MAPK14 Q16539 3/20 0.41
POLB P06746 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM1A O60341 1/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16747866 0.77 KMT2A (0.54) KMT2AMEN1GAAMAPTTDP1
SCHEMBL9738495 0.76 MAPT (0.60) KMT2AMEN1GAAMAPTTDP1
SCHEMBL16550246 0.76 KMT2A (0.60) KMT2AMEN1GAAMAPTTDP1
SCHEMBL16747857 0.74 CDK2 (0.60) KMT2AMEN1GAAMAPTTDP1
SCHEMBL4941362 0.74 MAPK10 (0.71) KMT2AMEN1GAAMAPTTDP1
SCHEMBL3719304 0.72 KMT2A (0.72) KMT2AMEN1GAAMAPTMAPK10
SCHEMBL18153309 0.71 MAPT (0.50) KMT2AMEN1GAAMAPTKDM4E
SCHEMBL13116584 0.71 MAPK10 (0.57) KMT2AMEN1GAAMAPTTDP1
SCHEMBL2944533 0.71 MAPT (0.69) KMT2AMEN1GAAMAPTTDP1
SCHEMBL9183066 0.71 MAPT (0.69) KMT2AMEN1GAAMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B KMT2A 132/4885MEN1 985/4885GAA 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.